Systematic review and meta-analysis of immune checkpoint inhibitors as single agent or in combination with chemotherapy in early-stage non-small cell lung cancer: Impact of clinicopathological factors and indirect comparison between treatment strategies
European Journal of Cancer · 2023-12 · 195 · 113404
DOI: 10.1016/j.ejca.2023.113404 ↗Kurz gefasst
Metaanalyse in der Zeitschrift European Journal of Cancer, 2023-12. Verfasst von Antonio Nuccio und 20 weiteren Autor:innen. Beteiligte Einrichtung: Università Vita-Salute San Raffaele, Milan, Italy; IRCCS Ospedale San Raffaele, Department of Medical Oncology, Milan, Italy. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma, Lung Neoplasms. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS.
Themen: Onkologische Pflege
Abstract (Originalsprache)
BACKGROUND: In non-small cell lung cancer (NSCLC), the immune checkpoint inhibitors (ICI) revolution is rapidly moving from metastatic to early-stage, however, the impact of clinicopathological variables and optimal treatment sequencing remain unclear. METHODS: Randomized controlled trials (RCTs) in patients with early-stage NSCLC treated with ICI as single agent or in combination with platinum-based chemotherapy (PCT) were included. Primary outcomes were pathological complete response (pCR), event free survival (EFS) (neoadjuvant/perioperative), and disease-free survival (DFS) (adjuvant). Secondary outcomes were major pathological response (MPR), overall survival (OS), toxicity, surgical outcomes (neoadjuvant/perioperative); OS and toxicity (adjuvant). An additional secondary endpoint was to compare EFS and OS between neoadjuvant and perioperative strategies. RESULTS: 8 RCTs (2 neoadjuvant, 4 perioperative, 2 adjuvant) (4661 participants) were included. Neoadjuvant/perioperative ICI+PCT significantly improved pCR, EFS, OS, MPR and R0 resection compared to PCT. Adjuvant ICI significantly improved DFS compared to placebo. There was a significant subgroup interaction by PD-L1 status (χ2 = 10.72, P = 0.005), pCR (χ2 = 17.80, P < 0.0001), and stage (χ2 = 4.46, P = 0.003) for EFS. No difference according to PD-L1 status was found for pCR, with 14% of patients having PD-L1 negative tumors still experiencing a pCR. No interaction by PD-L1 status was found for DFS upon adjuvant ICI. Indirect comparison showed no difference in EFS and OS between neoadjuvant and perioperative ICI+PCT. CONCLUSIONS: PD-L1 status, pCR and stage impact on survival upon neoadjuvant/perioperative ICI. The restriction of neoadjuvant/perioperative ICI to PD-L1 + patients could preclude pCR and long-term benefit in the PD-L1- subgroup. Neoadjuvant and perioperative could be equivalent strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Università Vita-Salute San Raffaele, Milan, Italy; IRCCS Ospedale San Raffaele, Department of Medical Oncology, Milan, Italy.
- Department of Pneumology and Oncology, PO Monaldi-AORN Ospedali dei Colli, Naples, Italy.
- Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
- IRCCS Ospedale San Raffaele, Department of Medical Oncology, Milan, Italy.
- Department of Medicine, University of Verona, Verona, Italy.
- Department of Medicine, Hematology Oncology Section, Thoracic Oncology Program, The University of Chicago, Chicago, USA.
Förderung
- NIGMS NIH HHS
Zitieren
APA
Nuccio, A., Viscardi, G., Salomone, F., Servetto, A., Venanzi, F. M., Riva, S. T., Oresti, S., Ogliari, F. R., Viganò, M., Bulotta, A., Cameron, R., Esposito, A., Hines, J., Bianco, R., Reni, M., Cascone, T., Garassino, M. C., Torri, V., Veronesi, G., …, & Ferrara, R. (2023). Systematic review and meta-analysis of immune checkpoint inhibitors as single agent or in combination with chemotherapy in early-stage non-small cell lung cancer: Impact of clinicopathological factors and indirect comparison between treatment strategies. European Journal of Cancer, 195, 113404. https://doi.org/10.1016/j.ejca.2023.113404
Vancouver
Nuccio A, Viscardi G, Salomone F, Servetto A, Venanzi FM, Riva ST, et al. Systematic review and meta-analysis of immune checkpoint inhibitors as single agent or in combination with chemotherapy in early-stage non-small cell lung cancer: Impact of clinicopathological factors and indirect comparison between treatment strategies. European Journal of Cancer. 2023;195:113404. doi:10.1016/j.ejca.2023.113404
BibTeX
@article{Nuccio2023,
author = {Nuccio, Antonio and Viscardi, Giuseppe and Salomone, Fabio and Servetto, Alberto and Venanzi, Francesco Maria and Riva, Silvia Teresa and Oresti, Sara and Ogliari, Francesca Rita and Viganò, Mariagrazia and Bulotta, Alessandra and Cameron, Robert and Esposito, Alessandra and Hines, Jacobi and Bianco, Roberto and Reni, Michele and Cascone, Tina and Garassino, Marina Chiara and Torri, Valter and Veronesi, Giulia and Cinquini, Michela and Ferrara, Roberto},
title = {Systematic review and meta-analysis of immune checkpoint inhibitors as single agent or in combination with chemotherapy in early-stage non-small cell lung cancer: Impact of clinicopathological factors and indirect comparison between treatment strategies},
journal = {European Journal of Cancer},
year = {2023},
volume = {195},
pages = {113404},
doi = {10.1016/j.ejca.2023.113404}
}
EUVIMED